Galeterone Shows Promising Results In Castration-Resistant Prostate Cancer

Galeterone Shows Promising Results In Castration-Resistant Prostate Cancer
Recent results from a clinical study (ARMOR2) assessing the anti-cancer drug galeterone, revealed it could successfully lower prostate-specific antigen (PSA) levels in patients who suffer from castration-resistant prostate cancer (CRPC). The data was presented by associate professor Mary-Ellen Taplin, of the Dana-Farber Cancer Institute during the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *